Silicon Valley’s bipartisan political action committee endorsed the Trans Pacific Partnership agreement Monday – a pact on which Rep. Mike Honda has not yet taken a final position, and which his Democratic challenger, Ro Khanna, opposes.
TechNet, a policy and political network of tech CEOs and senior executives, endorsed the free-trade pact Monday and urged Congress to approve it.
“The U.S. technology sector has grown into a leading force in the U.S. economy, fueled by an unparalleled commitment to innovation and an unprecedented investment in research and development,” President and CEO Linda Moore said in a news release. “The statistics are staggering: the U.S. innovation economy now supports more than 30 percent of U.S. GDP and employs more than 6.5 million Americans. It’s being driven by the incredible new technologies developed in Silicon Valley, Seattle, Austin, Boston, and beyond, and it’s been accelerated by international trade.”
“Yet, our nation’s ability to continue to lead in this sector is dependent on access to the fastest growing markets in the world and the uninhibited flow of data across borders,” she continued. “This agreement supports U.S. technology leadership around the globe, and will drive economic growth and job creation here at home.”
President Obama is likely to call for the TPP’s passage during his State of the Union address to Congress on Tuesday night. But Honda, D-San Jose, has not yet taken a position on the agreement negotiated between the United States and 11 Pacific Rim trading partners, Chief of Staff Jennifer Van der Heide said Monday.
He did vote last year against the Trade Promotion Authority that allowed the Obama administration to fast-track this trade pact, calling for Congress to have a bigger role in its drafting. And he has spoken about making sure agreements like this include strong, clear and enforceable labor, environmental and human rights standards.
Khanna said Monday he would vote against the Trans Pacific Partnership.
“First, the tribunals that have been set up to adjudicate give too much power to corporations and don’t take labor, environmental and human rights stakeholders into consideration,” he said via email. “Second, there is too much of an IP and data exclusivity giveaway to pharmaceuticals that would deprive many people around the world of access to drugs.”